Cephalon Inc reported second quarter 2010 sales were up 32% from Q209, helped by a boost in sales of Provigil and Nuvigil, prescription medications for the treatment of sleep disorders.
Sales of Nuvigil rose to $41 million from $34.9 million in the previous quarter. Provigil sales rose 9%. Central nervous system and oncology franchise sales were also up 16% and 58%, respectively. Meanwhile, the company’s pain franchise sales slipped 8%. Other product sales were up 208% versus the second quarter of 2009 due to the expansion of the company’s European business.
Overall, adjusted net income for the second quarter of 2010 was $165.3 million, a 49% increase over the comparable $110.7 million for the second quarter of 2009.
